Furosemide versus mannitol in Japanese patients with thoracic malignancy who received cisplatin-based chemotherapy using short hydration: study protocol for a randomised controlled trial
Introduction Cisplatin (CDDP) is a key drug for various thoracic malignancies. To avoid renal toxicity of CDDP, mannitol is routinely used, but it sometimes causes phlebitis which damages patients’ quality of life. Furosemide is another widely used option for diuresis administered more quickly. To d...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2019-12-01
|
| Series: | BMJ Open |
| Online Access: | https://bmjopen.bmj.com/content/9/12/e029057.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850056158641913856 |
|---|---|
| author | Eriko Murakami Hiroaki Akamatsu Toshio Shimokawa Kiyoko Wada Nobuyuki Yamamoto |
| author_facet | Eriko Murakami Hiroaki Akamatsu Toshio Shimokawa Kiyoko Wada Nobuyuki Yamamoto |
| author_sort | Eriko Murakami |
| collection | DOAJ |
| description | Introduction Cisplatin (CDDP) is a key drug for various thoracic malignancies. To avoid renal toxicity of CDDP, mannitol is routinely used, but it sometimes causes phlebitis which damages patients’ quality of life. Furosemide is another widely used option for diuresis administered more quickly. To date, previous comparisons of these diuretics have lacked statistical significance owing to study design. We therefore undertake a randomised phase II comparative study of furosemide and mannitol in CDDP-based chemotherapy using short hydration.Methods and analysis This is a two-arm, prospective, randomised, single-centre, open-label phase II study. The primary endpoint is set as the proportion of patients who experienced any grade of ‘creatinine increase’ using the Common Terminology Criteria for Adverse Events V.4.0, during the first cycle. Secondary endpoints are: the proportion of patients who experienced ≥grade 2 of creatinine increase during the first cycle, any grade and ≥grade 2 of creatinine increase after the completion of fourth cycle, and the proportion of patients with phlebitis. Enrolled in this trial will be 105 patients.Ethics and dissemination This study was approved by the Wakayama Medical University Institutional Review Board on 30 March 2018 study (approval number: 2258). Patients have been enrolled since May 2018. As the study will complete accrual in March 2021, results will be published by 2021. This study will provide important information about the utility of furosemide compared with mannitol to protect against nephrotoxicity.Trial registration number UMIN000031910. |
| format | Article |
| id | doaj-art-14fee154a1b248d58dade8c784d4fd2e |
| institution | DOAJ |
| issn | 2044-6055 |
| language | English |
| publishDate | 2019-12-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | BMJ Open |
| spelling | doaj-art-14fee154a1b248d58dade8c784d4fd2e2025-08-20T02:51:46ZengBMJ Publishing GroupBMJ Open2044-60552019-12-0191210.1136/bmjopen-2019-029057Furosemide versus mannitol in Japanese patients with thoracic malignancy who received cisplatin-based chemotherapy using short hydration: study protocol for a randomised controlled trialEriko Murakami0Hiroaki Akamatsu1Toshio Shimokawa2Kiyoko Wada3Nobuyuki Yamamoto4Internal Medicine III, Wakayama Medical University, Wakayama, JapanInternal Medicine Ⅲ, Wakayama Medical University, Wakayama, JapanClinical Study Support Center, Wakayama Medical University Hospital, Wakayama, JapanDepartment of Nursing, Wakayama Medical University, Wakayama, Japan2 Department of Surgery, Kansai Medical University, Hirakata, Osaka, JapanIntroduction Cisplatin (CDDP) is a key drug for various thoracic malignancies. To avoid renal toxicity of CDDP, mannitol is routinely used, but it sometimes causes phlebitis which damages patients’ quality of life. Furosemide is another widely used option for diuresis administered more quickly. To date, previous comparisons of these diuretics have lacked statistical significance owing to study design. We therefore undertake a randomised phase II comparative study of furosemide and mannitol in CDDP-based chemotherapy using short hydration.Methods and analysis This is a two-arm, prospective, randomised, single-centre, open-label phase II study. The primary endpoint is set as the proportion of patients who experienced any grade of ‘creatinine increase’ using the Common Terminology Criteria for Adverse Events V.4.0, during the first cycle. Secondary endpoints are: the proportion of patients who experienced ≥grade 2 of creatinine increase during the first cycle, any grade and ≥grade 2 of creatinine increase after the completion of fourth cycle, and the proportion of patients with phlebitis. Enrolled in this trial will be 105 patients.Ethics and dissemination This study was approved by the Wakayama Medical University Institutional Review Board on 30 March 2018 study (approval number: 2258). Patients have been enrolled since May 2018. As the study will complete accrual in March 2021, results will be published by 2021. This study will provide important information about the utility of furosemide compared with mannitol to protect against nephrotoxicity.Trial registration number UMIN000031910.https://bmjopen.bmj.com/content/9/12/e029057.full |
| spellingShingle | Eriko Murakami Hiroaki Akamatsu Toshio Shimokawa Kiyoko Wada Nobuyuki Yamamoto Furosemide versus mannitol in Japanese patients with thoracic malignancy who received cisplatin-based chemotherapy using short hydration: study protocol for a randomised controlled trial BMJ Open |
| title | Furosemide versus mannitol in Japanese patients with thoracic malignancy who received cisplatin-based chemotherapy using short hydration: study protocol for a randomised controlled trial |
| title_full | Furosemide versus mannitol in Japanese patients with thoracic malignancy who received cisplatin-based chemotherapy using short hydration: study protocol for a randomised controlled trial |
| title_fullStr | Furosemide versus mannitol in Japanese patients with thoracic malignancy who received cisplatin-based chemotherapy using short hydration: study protocol for a randomised controlled trial |
| title_full_unstemmed | Furosemide versus mannitol in Japanese patients with thoracic malignancy who received cisplatin-based chemotherapy using short hydration: study protocol for a randomised controlled trial |
| title_short | Furosemide versus mannitol in Japanese patients with thoracic malignancy who received cisplatin-based chemotherapy using short hydration: study protocol for a randomised controlled trial |
| title_sort | furosemide versus mannitol in japanese patients with thoracic malignancy who received cisplatin based chemotherapy using short hydration study protocol for a randomised controlled trial |
| url | https://bmjopen.bmj.com/content/9/12/e029057.full |
| work_keys_str_mv | AT erikomurakami furosemideversusmannitolinjapanesepatientswiththoracicmalignancywhoreceivedcisplatinbasedchemotherapyusingshorthydrationstudyprotocolforarandomisedcontrolledtrial AT hiroakiakamatsu furosemideversusmannitolinjapanesepatientswiththoracicmalignancywhoreceivedcisplatinbasedchemotherapyusingshorthydrationstudyprotocolforarandomisedcontrolledtrial AT toshioshimokawa furosemideversusmannitolinjapanesepatientswiththoracicmalignancywhoreceivedcisplatinbasedchemotherapyusingshorthydrationstudyprotocolforarandomisedcontrolledtrial AT kiyokowada furosemideversusmannitolinjapanesepatientswiththoracicmalignancywhoreceivedcisplatinbasedchemotherapyusingshorthydrationstudyprotocolforarandomisedcontrolledtrial AT nobuyukiyamamoto furosemideversusmannitolinjapanesepatientswiththoracicmalignancywhoreceivedcisplatinbasedchemotherapyusingshorthydrationstudyprotocolforarandomisedcontrolledtrial |